Search results :

ICI 182,780

More information: STITCH, PubChem and possibly Wikipedia

ATC Code: L02BA03

Side effects

Options: Show MedDRA Preferred Terms

Side effect Data for drug Placebo Labels
1 2 3
Asthenia postmarketing, 5.82% - 27% x x x
Nausea postmarketing, 9.7% - 26% x x x
Pain postmarketing, 18.9% - 20.3% x x
Malnutrition 17.7% - 18.2% x x x
Vasodilation postmarketing, 17.3% - 17.7% x
Headache postmarketing, 6.68% - 16.8% x x x
Pharyngitis 11.6% - 16.1% x x
Bone pain 7.49% - 15.8% x x
Back pain 7.48% - 14.4% x x x
Diarrhoea postmarketing, 12.3% - 12.8% x x x
Dyspnoea 4.43% - 14.9% x x
Vomiting postmarketing, 5.61% - 13% x x x
Abdominal pain 11.6% - 11.8% x x
Constipation 3.48% - 12.5% x x
Cough increased 10.4% x x
Injection site pain 6.6% - 11.6% x x
Oedema peripheral 9% - 10.2% x x
Pelvic pain 9% - 9.9% x x
Anorexia postmarketing, 3.74% - 10.9% x x x
Arthralgia 7.75% - 8.03% x
Insomnia 6.9% - 8.5% x x
Rash postmarketing, 7.3% - 8% x x x
Paraesthesia 6.4% - 7.6% x x
Fatigue 6.42% - 7.48% x
Pain in extremity 6.93% - 6.95% x
Dizziness 6.6% - 6.9% x x
Influenza 6.4% - 7.1% x x
Body temperature increased 6.4% x x
Depression 5.7% - 6.9% x x
Chest pain 5% - 7.1% x x
Cough 5.26% - 5.35% x
Sweating 5% - 5.2% x x
Accidental injury 4.5% - 5.7% x x
Anaemia 4.5% - 5% x x
Arthritis 2.8% - 6.1% x x
Anxiety 3.8% - 5% x x
Musculoskeletal pain 3.21% - 5.54% x
Urinary tract infection postmarketing, 3.5% - 6.1% x x x
Hot flush postmarketing, 5.88% - 6.65% x x x
Angioedema postmarketing x x
Haemorrhage postmarketing x
Hepatitis postmarketing x
Hypersensitivity postmarketing x x x
Inflammation postmarketing x x
Leukopenia postmarketing x
Pruritus postmarketing x
Urticaria postmarketing x x
Vertigo postmarketing x
Hepatic failure postmarketing x x
Injection site reaction postmarketing x x x
Myalgia postmarketing x
Digestion impaired postmarketing x
Hepatic enzyme increased postmarketing x
Breast cancer stage IV postmarketing x
Vaginal haemorrhage postmarketing x x
Breast disorder x
Vaginal moniliasis x
Infection x
Connective tissue disorder x
Gastrointestinal disorder x
Hepatitis C x
Immune system disorder x
Leukorrhea x
Nervous system disorder x
Angiopathy x
Gamma-glutamyltransferase increased x
Injection site haemorrhage x
Unspecified disorder of skin and subcutaneous tissue x
Hepatobiliary disease x
Blood bilirubin increased x
Gastrointestinal symptom NOS x
Injection site haematoma x
Infestation NOS x
Venous thromboembolism x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

fulvestrant / fulvestrant

Side effects:33
Source:EMA

FULVESTRANT / FASLODEX

Side effects:43
Source:Health Canada

FULVESTRANT

Side effects:51
Source:FDA Structured Product Label

Color scheme:

standard – alternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label